---

---

therapeutics   tags : License   

save search

---

YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
YS | News | $0.87 -7.05% -7.59% 350K |

n/a

| 0.0% | O: -7.45% H: 0.0% C: 0.0%
hepatitis vaccine license granted biopharma virus trial

---

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
Published: 2024-03-28 (Crawled : 11:00) - globenewswire.com
XLO | $1.23 0.0% 150K |

Professional, Scientific, and T...

| 92.49% | O: 200.47% H: 0.52% C: -43.75%
GILD | News | $66.16 -1.15% -1.16% 6.4M |

Health Technology

| -8.33% | O: 0.33% H: 0.85% C: 0.0%
il-12 license program agreement

---

Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE
Published: 2024-03-22 (Crawled : 08:00) - biospace.com/
RLFTF | $1.4 11.45% 1.3K |

n/a

| -4.44% | O: -3.07% H: 18.31% C: 12.54%
ETON | $3.12 -0.64% -0.64% 67K |

Health Technology

| -11.88% | O: 6.08% H: 5.73% C: 3.13%
license pharmaceuticals golike therapeutics agreement

---

Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
Published: 2024-03-20 (Crawled : 12:30) - globenewswire.com
SILO | $1.96 1.02% 6.6K |

Finance and Insurance

| 12.0% | O: 1.71% H: 1.12% C: 1.12%
pharma license agreement

---

ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency
Published: 2024-03-19 (Crawled : 12:00) - globenewswire.com
CLPT | $5.39 -2.53% -2.6% 87K |

Health Technology

| -21.07% | O: 0.0% H: 0.99% C: -1.27%
fda license treatment application therapeutics submission

---

Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda
Published: 2024-03-18 (Crawled : 12:00) - biospace.com/
PTGX | $25.23 -1.33% -1.35% 390K |

Health Technology

| -11.77% | O: -0.59% H: 1.42% C: -1.21%
license worldwide collaboration therapeutics agreement

---

Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK
Published: 2024-02-26 (Crawled : 15:30) - biospace.com/
COEP | $0.3699 -1.18% 51K |

| -24.7% | O: 9.89% H: 7.41% C: 0.0%
license therapeutics agreement

---

Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan
Published: 2024-02-20 (Crawled : 13:30) - globenewswire.com
TENX | $3.67 2.23% 2.18% 21K |

Health Technology

| -13.49% | O: 1.93% H: 5.2% C: -5.67%
license levosimendan global therapeutics

---

Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics
Published: 2024-02-15 (Crawled : 00:00) - prnewswire.com
ALPMY | $9.46 -1.11% 500K |

Manufacturing

| -15.48% | O: -2.99% H: 3.82% C: 3.54%
license research therapeutics agreement

---

Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis
Published: 2024-02-05 (Crawled : 23:00) - biospace.com/
XCUR 4 | $0.5838 -2.29% -2.35% 24K |

Commercial Services

| 10.29% | O: 1.1% H: 1.82% C: 1.76%
hepatitis patent license treatment therapeutics agreement

---

Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)
Published: 2024-02-01 (Crawled : 12:30) - globenewswire.com
ABEO | $7.55 -4.79% -5.03% 250K |

Health Technology

| 75.76% | O: -1.13% H: 0.0% C: 0.0%
license update application therapeutics

---

Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203
Published: 2024-01-25 (Crawled : 12:30) - globenewswire.com
AMRX | $5.36 -1.83% -1.87% 840K |

Health Technology

| 0.37% | O: 1.57% H: 0.73% C: -0.82%
ipx203 license pharmaceuticals therapeutics agreement

---

Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)
Published: 2024-01-22 (Crawled : 12:00) - globenewswire.com
AUTL | $4.8 -0.83% -0.83% 1.2M |

Health Technology

| -20.46% | O: 2.45% H: 2.72% C: -8.15%
license treatment application leukemia therapeutics potential

---

Windtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region
Published: 2024-01-17 (Crawled : 13:00) - globenewswire.com
WINT | News | $0.3399 -15.3% -18.06% 1.8M |

Health Technology

| -32.19% | O: 1.71% H: 0.0% C: -19.42%
license pharmaceuticals asia therapeutics agreement china

---

Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases
Published: 2024-01-09 (Crawled : 13:30) - biospace.com/
TGTX | News | $14.0 1.3% 1.29% 3.5M |

Health Technology

| -35.12% | O: -8.22% H: 9.05% C: 7.47%
DTIL | $10.77 -6.43% -6.87% 71K |

Health Technology

| 3133.67% | O: 10.0% H: 14.23% C: 0.09%
license cell treatment deal therapeutics therapy

---

TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases
Published: 2024-01-09 (Crawled : 12:00) - globenewswire.com
TGTX | News | $14.0 1.3% 1.29% 3.5M |

Health Technology

| -35.12% | O: -8.22% H: 9.05% C: 7.47%
DTIL | $10.77 -6.43% -6.87% 71K |

Health Technology

| 3133.67% | O: 10.0% H: 14.23% C: 0.09%
cd19 license cell treatment global commercialization program therapeutics agreement therapy

---

Simcha Therapeutics Announces License & Option Agreement to Develop Novel Decoy-resistant IL-18 for Use in Cell Therapy Applications
Published: 2024-01-08 (Crawled : 14:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M |

Health Technology

| -9.8% | O: 0.47% H: 0.0% C: 0.0%
il-18 license cell therapeutics agreement therapy

---

Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca
Published: 2024-01-02 (Crawled : 14:00) - prnewswire.com
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| 1.36% | O: -0.76% H: 2.65% C: 2.33%
license astrazeneca global program therapeutics agreement

---

Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies
Published: 2024-01-02 (Crawled : 12:00) - globenewswire.com
NVS | $92.57 -0.55% 0.0% 910K |

Health Technology

| -7.81% | O: -0.86% H: 1.81% C: 0.9%
VYGR | $7.55 -2.46% -2.52% 1M |

Health Technology

| -8.29% | O: 24.76% H: 11.3% C: -14.53%
SGMO | $0.4853 -5.95% -6.33% 1.7M |

Health Technology

| -4.29% | O: -0.17% H: 9.33% C: 2.56%
NBIX M | $132.49 -0.56% -0.56% 550K |

Health Technology

| 1.12% | O: -1.18% H: 2.4% C: 1.18%
license collaboration novartis therapeutics agreement

---

Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in Canada
Published: 2023-12-19 (Crawled : 12:30) - globenewswire.com
SUPN | $28.88 -0.41% -0.42% 350K |

Health Technology

| 6.27% | O: 1.14% H: 3.41% C: 1.85%
qelbree license pharmaceuticals canada therapeutics agreement

---

Gainers vs Losers

64%

36%

Top 10 Gainers

AGBA | News | $1.02 155.0% 57.94% 120M |

Finance

ZCMD | $2.86 108.76% 52.1% 2.3M |

Commercial Services

INVO | $1.555 104.6% 51.13% 5M |

Health Technology

ISPC | $0.437 105.16% 49.53% 37M |

Professional, Scientific, and T...

WLGS | News | $0.92 84.0% 45.65% 1.6M |

OST | $0.499 21.38% 45.26% 1.9M |

XPON | News | $3.1 60.62% 37.74% 17M |

TIRX | $0.7 44.39% 30.74% 58M |

BNTC | News | $6.92 44.17% 30.64% 3.5M |

Health Technology

GGE | $0.035 19.86% 29.3% 64M |

---

Your saved searches

---